Key Highlights

  • Abbott reported second-quarter 2026 worldwide sales of $11.14 billion, with reported sales growth of 10.8% and organic growth of 8.3%, reflecting broad-based momentum across its healthcare portfolio.
  • The company raised its full-year 2026 adjusted EPS guidance to a range of $5.23 to $5.33 after delivering another quarter of strong earnings and margin expansion.
  • Medical Devices remained the biggest growth driver, led by continued expansion of the FreeStyle Libre franchise and robust demand for cardiovascular technologies.
  • Diagnostics, Nutrition and Established Pharmaceuticals all contributed to revenue growth, highlighting the strength of Abbott's diversified business model.
  • Strong cash generation, continued innovation and healthy performance across key business segments reinforced Abbott's long-term growth outlook despite a challenging macroeconomic environment.

Abbott Delivers Another Strong Quarter as Broad-Based Growth Drives Higher Earnings Outlook

Abbott strengthened its investment case during the second quarter of 2026 after reporting another quarter of double-digit reported sales growth, expanding profitability and strong operating performance across nearly every major business segment. The healthcare giant not only exceeded expectations on several key financial metrics but also raised its full-year earnings guidance, signaling confidence that demand across its diversified portfolio will remain resilient through the remainder of the year.

The results highlight Abbott's ability to generate consistent growth despite operating in an environment characterized by inflationary pressures, evolving healthcare spending patterns and increasing competition across several medical technology markets. Rather than relying on a single product or therapeutic area, the company continues benefiting from multiple growth engines spanning medical devices, diagnostics, nutrition and established pharmaceuticals, allowing it to deliver stable financial performance across different market conditions.

For the quarter ended June 30, 2026, Abbott reported worldwide sales of $11.14 billion, representing an increase of 10.8% on a reported basis and 8.3% organically compared with the same period last year. Excluding COVID-19 testing-related sales, underlying demand remained healthy across the company's core businesses, demonstrating that Abbott has successfully transitioned beyond pandemic-related revenue and is now generating growth from its broader healthcare portfolio.

Profitability also continued to improve during the quarter. The company reported GAAP diluted earnings per share of $1.33, while adjusted diluted earnings per share reached $1.28, reflecting strong operating execution, improving product mix and disciplined cost management. The earnings performance further reinforced Abbott's reputation as one of the healthcare sector's most consistent earnings compounders.

Raised Full-Year EPS Guidance Reflects Growing Confidence

Perhaps the most significant announcement accompanying the quarterly results was Abbott's decision to increase its earnings outlook for the remainder of 2026.

The company raised its full-year adjusted diluted EPS guidance to a range of $5.23 to $5.33, representing an increase from its previous forecast and indicating that management expects current business momentum to continue throughout the second half of the year.

A guidance increase carries greater significance than a single quarter of strong results because it reflects expectations for sustained operational performance rather than temporary strength. The revised outlook suggests Abbott expects continued volume growth, favorable product mix, stable pricing and ongoing margin expansion across its major operating businesses.

The updated earnings forecast also demonstrates confidence in Abbott's ability to navigate macroeconomic uncertainty while continuing to invest in research, manufacturing capacity and product innovation. Rising productivity, operational efficiencies and disciplined expense management have helped offset higher input costs without materially affecting profitability.

For investors, the guidance increase reinforces the view that Abbott's diversified operating model remains capable of delivering dependable earnings growth even as broader economic conditions remain uncertain.

Medical Devices Continue to Lead Revenue Growth

Medical Devices once again emerged as Abbott's strongest-performing business and remained the primary driver of overall revenue growth during the second quarter.

The segment generated approximately $5.34 billion in quarterly sales, increasing by nearly 15% year over year, supported by strong demand across diabetes care, cardiovascular devices, structural heart therapies and neuromodulation products.

Among these businesses, the FreeStyle Libre continuous glucose monitoring franchise continued to serve as Abbott's largest individual growth engine. The platform has maintained strong global adoption as physicians increasingly recommend continuous glucose monitoring for a broader range of diabetes patients. Expansion across both Type 1 and Type 2 diabetes populations, improving reimbursement coverage and continued international market penetration have significantly strengthened the franchise's growth trajectory.

The Libre ecosystem has evolved beyond traditional glucose monitoring by offering improved connectivity, enhanced digital capabilities and greater convenience for patients managing chronic diabetes. These factors continue supporting higher adoption rates across developed as well as emerging healthcare markets.

Cardiovascular devices also contributed meaningfully to quarterly growth. Abbott continued benefiting from rising procedural volumes in structural heart interventions, electrophysiology and heart failure therapies as hospitals maintained strong demand for minimally invasive cardiovascular treatments.

The combination of diabetes care and cardiovascular technologies has positioned Medical Devices as Abbott's largest long-term growth platform, providing recurring revenue opportunities while supporting expanding operating margins.

Diagnostics Business Continues Building Momentum Beyond COVID-19

Abbott's Diagnostics business delivered another encouraging quarter as the company continued replacing pandemic-related testing revenue with sustainable growth across its core diagnostics portfolio.

The segment reported approximately $2.16 billion in quarterly revenue, driven by improving demand across laboratory diagnostics, rapid diagnostics and molecular testing solutions.

Excluding COVID-19 testing products, core diagnostics continued benefiting from higher hospital utilization, increasing routine testing volumes and expanding adoption of advanced laboratory technologies worldwide. Healthcare systems across major international markets have continued normalizing patient activity, resulting in stronger recurring demand for Abbott's diagnostic platforms.

The ongoing recovery is particularly important because Diagnostics remains one of Abbott's highest-value businesses over the long term. As testing volumes continue recovering and healthcare utilization improves globally, the segment is expected to generate stable recurring revenue while contributing positively to future operating margin expansion.

The company's ability to successfully transition away from pandemic-driven testing revenue demonstrates the resilience of its broader diagnostics portfolio and reinforces investor confidence in its long-term growth strategy.

Nutrition and Established Pharmaceuticals Reinforce Abbott's Diversified Business Model

While Medical Devices and Diagnostics attracted most investor attention during the quarter, Abbott's Nutrition and Established Pharmaceuticals businesses continued providing important contributions to the company's overall financial performance.

The Nutrition segment generated approximately $2.15 billion in revenue during the second quarter, supported by continued demand across both adult and pediatric nutrition products. Global brands such as Ensure, PediaSure and Abbott's infant nutrition portfolio continued demonstrating resilient demand despite varying consumer spending patterns across international markets.

Nutrition remains one of Abbott's most dependable businesses because demand for essential nutritional products tends to remain relatively stable regardless of economic conditions. Continued innovation and geographic expansion have further strengthened the segment's long-term growth profile.

Meanwhile, Established Pharmaceuticals generated approximately $1.39 billion in quarterly sales, driven primarily by sustained demand across emerging markets where Abbott maintains one of the industry's broadest branded generic pharmaceutical portfolios.

Although this business grows at a more moderate pace than Medical Devices, it provides valuable geographic diversification while generating consistent cash flows that support investment across Abbott's faster-growing businesses.

Together, Nutrition and Established Pharmaceuticals highlight one of Abbott's greatest competitive strengths—a balanced portfolio capable of delivering consistent revenue growth across multiple healthcare categories rather than relying on any single product or therapeutic area.

Innovation Pipeline and FreeStyle Libre Continue to Shape Abbott's Long-Term Growth Story

While Abbott's second-quarter financial performance attracted significant attention, the company's long-term investment thesis continues to revolve around sustained innovation across its medical technology portfolio. Among all its growth platforms, FreeStyle Libre remains one of the most important contributors to future revenue expansion and competitive positioning.

The continuous glucose monitoring (CGM) market continues expanding rapidly as healthcare providers increasingly recommend continuous monitoring for a broader population of diabetes patients. Rising global diabetes prevalence, earlier diagnosis, improving reimbursement policies and greater awareness of glucose management have significantly increased adoption of CGM technology across developed and emerging markets.

Abbott has continued strengthening the Libre ecosystem through product enhancements, expanded digital connectivity and broader compatibility with insulin delivery systems and healthcare platforms. These developments have helped the company maintain one of the largest installed user bases in the global CGM market while expanding its addressable patient population beyond intensive insulin users.

Beyond diabetes care, Abbott continues investing heavily across structural heart, electrophysiology, heart failure, neuromodulation and vascular technologies. Demand for minimally invasive cardiovascular procedures continues increasing as aging populations and higher rates of chronic cardiovascular disease drive greater utilization of advanced medical devices.

The company's diversified innovation pipeline reduces dependence on any single product cycle while creating multiple opportunities for long-term revenue expansion. New product launches, regulatory approvals and broader geographic commercialization are expected to provide additional growth catalysts over the coming years.

Unlike many healthcare companies that rely primarily on pharmaceutical patent cycles, Abbott's medical technology portfolio benefits from continuous product improvements and recurring demand, creating a more stable long-term growth profile.

Strategic Portfolio Expansion Strengthens Abbott's Competitive Position

Abbott has also continued strengthening its long-term strategy through disciplined portfolio expansion and targeted investments designed to enhance future growth opportunities.

During the quarter, the company announced its planned acquisition of Exact Sciences' blood-based cancer screening business, a transaction expected to expand Abbott's presence in one of the fastest-growing areas of preventive healthcare.

The acquisition provides access to advanced molecular diagnostic technologies focused on early cancer detection, complementing Abbott's existing diagnostics business while expanding its capabilities within precision medicine.

Blood-based cancer screening is expected to become an increasingly important area of healthcare over the coming decade as technological advances improve early disease detection and screening adoption continues to increase globally.

Rather than transforming Abbott's business overnight, the transaction represents another example of the company's disciplined capital allocation strategy—adding innovative technologies that fit within existing healthcare platforms while creating opportunities for long-term revenue growth.

Combined with ongoing investment across diagnostics, cardiovascular care and diabetes management, Abbott continues building a healthcare portfolio positioned to benefit from several structural industry trends simultaneously.

Strong Cash Flow Supports Innovation, Shareholder Returns and Future Growth

One of Abbott's greatest competitive advantages remains its ability to consistently generate strong operating cash flow while simultaneously investing in future growth initiatives.

The company's diversified business model produces recurring revenue across multiple healthcare segments, allowing it to maintain substantial investment in research and development without compromising profitability or financial flexibility.

This financial strength enables Abbott to pursue several capital allocation priorities simultaneously, including product innovation, manufacturing expansion, strategic acquisitions, dividend growth and share repurchases.

Abbott also remains one of the healthcare sector's most consistent dividend-paying companies, extending its long history of annual dividend increases while maintaining sufficient financial resources to fund future innovation.

For long-term investors, this balance between shareholder returns and growth investment represents a significant competitive advantage. Rather than sacrificing near-term profitability to finance expansion, Abbott continues generating enough cash to support both objectives simultaneously.

As healthcare spending continues rising worldwide, the company's financial flexibility should allow it to capitalize on new opportunities while maintaining a disciplined balance sheet.

Diversification Remains Abbott's Biggest Competitive Strength

Perhaps the most significant takeaway from Abbott's second-quarter performance is the continued strength of its diversified operating model.

Unlike healthcare companies that depend heavily on one blockbuster drug or a narrow product portfolio, Abbott generates meaningful revenue across Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals.

This diversification provides several important advantages.

Strong performance in one segment can offset temporary weakness elsewhere, reducing earnings volatility and improving financial resilience during changing market conditions.

Medical Devices currently represent the company's fastest-growing business, driven by diabetes care and cardiovascular technologies. Diagnostics continue recovering following the normalization of COVID-19 testing demand, while Nutrition delivers stable recurring revenue supported by globally recognized consumer brands. Established Pharmaceuticals further strengthen the portfolio through broad exposure to emerging healthcare markets.

This balanced business mix allows Abbott to participate in multiple long-term healthcare trends simultaneously, including aging populations, increasing chronic disease prevalence, greater access to medical technology, expanding diagnostic testing and rising demand for preventive healthcare solutions.

As a result, Abbott remains less dependent on individual product cycles than many of its healthcare peers, providing investors with greater visibility into long-term earnings growth.

Opportunities and Risks Investors Should Watch

Although Abbott continues delivering strong operational performance, investors should continue monitoring several factors that could influence future financial results.

Competition within the continuous glucose monitoring market remains intense as major industry participants continue investing aggressively in new technologies, product innovation and expanded global distribution. Maintaining leadership within diabetes care will require continued innovation and successful commercialization of future Libre platforms.

Foreign exchange fluctuations also remain an important consideration given Abbott's significant international operations. Currency movements can affect reported revenue and earnings even when underlying business performance remains strong.

Healthcare reimbursement policies, regulatory approvals and pricing dynamics across major global markets may also influence future growth rates, particularly within Medical Devices and Diagnostics.

In addition, the successful integration of acquired technologies and continued execution across multiple business segments will remain essential to sustaining Abbott's long-term growth trajectory.

Despite these considerations, the company's diversified revenue base, strong balance sheet, recurring cash generation and broad innovation pipeline position it well to navigate evolving industry conditions.

Investment Outlook

Abbott's second-quarter 2026 results reinforce the company's position as one of the healthcare sector's most consistent long-term performers.

Double-digit reported revenue growth, expanding profitability and a higher full-year earnings outlook demonstrate that the company's growth strategy continues producing measurable financial results. More importantly, strength was evident across nearly every major business segment rather than being concentrated within a single product line.

Medical Devices continue driving above-market growth through the expanding FreeStyle Libre franchise and cardiovascular technologies, while Diagnostics steadily recover beyond pandemic-related demand. Nutrition and Established Pharmaceuticals provide additional stability through recurring revenue streams that strengthen overall financial performance.

The decision to raise 2026 adjusted EPS guidance to $5.23–$5.33 reflects confidence that current business momentum will continue through the second half of the year. Combined with continued investment in innovation, strategic acquisitions and disciplined capital allocation, Abbott appears well positioned to capitalize on long-term healthcare demand across multiple global markets.

While investors should continue monitoring competitive dynamics, regulatory developments and macroeconomic conditions, Abbott's diversified operating model, strong financial foundation and expanding innovation pipeline continue supporting a favorable long-term investment outlook.

Q. Why did Abbott raise its 2026 earnings guidance?

A. Abbott increased its full-year 2026 adjusted diluted EPS guidance to $5.23–$5.33 after reporting stronger-than-expected second-quarter performance. The higher outlook reflects broad-based revenue growth, expanding margins and continued strength across Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals.

Q. What were Abbott's key financial results for Q2 2026?

A. Abbott reported worldwide sales of $11.14 billion, representing 10.8% reported sales growth and 8.3% organic growth. The company also delivered GAAP diluted EPS of $1.33 and adjusted diluted EPS of $1.28, while increasing its full-year earnings guidance.

Q. Which business segment contributed the most to Abbott's growth during the quarter?

A. Medical Devices remained Abbott's fastest-growing business, generating approximately $5.34 billion in quarterly revenue with nearly 15% year-over-year growth. Continued expansion of the FreeStyle Libre continuous glucose monitoring franchise and strong demand for cardiovascular products were the primary drivers.

Q. What are the biggest growth opportunities for Abbott over the next few years?

A. Abbott's long-term growth is expected to be supported by the continued global expansion of FreeStyle Libre, increasing adoption of cardiovascular and structural heart technologies, recovery in Diagnostics, expansion into blood-based cancer screening through its planned acquisition of Exact Sciences' screening business, and sustained investment in product innovation across its healthcare portfolio.